Hori Hikaru
   Department   School of Medicine  Psychiatry, Clinical Medical Sciences
Article types journal article
Language English
Peer review Peer reviewed
Title Efficacy, Tolerability, and Safety of Blonanserin in Schizophrenia: An Updated and Extended Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Journal Formal name:Pharmacopsychiatry
ISSN code:14390795/01763679
Domestic / ForeginForegin
Volume, Issue, Page 0頁
Author and coauthor Kishi Taro, Matsui Yuki, Matsuda Yuki, Katsuki Asuka, Hori Hikaru, Yanagimoto Hiroko, Sanada Kenji, Morita Kiichiro, Yoshimura Reiji, Shoji Yoshihisa, Hagi Katsuhiko, Iwata Nakao
Publication date 2018/03
Summary INTRODUCTION:We conducted an updated systematic review and meta-analysis of randomized controlled trials (RCTs) comparing blonanserin with other antipsychotics (amisulpride, aripiprazole, haloperidol, paliperidone, and risperidone).METHODS:Weighted mean difference (WMD), risk ratio, and number needed to harm (NNH) with 95% confidence intervals (95% CIs) were calculated using random-effects model.RESULTS:Ten RCTs (n=1521) were included in this study. Blonanserin was superior to aripiprazole in improvement of Positive and Negative Syndrome Scale total scores (WMD=-10.62, 95% CI=-17.67 to -3.560, p=0.003). Blonanserin was associated with a higher incidence of all-cause discontinuation (RR=1.373, 95% CI=1.088-1.734, p=0.008, NNH=11), akathisia, extrapyramidal disorder, and agitation/excitement and a lower risk of hyperprolactinemia compared with risperidone + paliperidone.DISCUSSION:The current meta-analytic study did not update the comparison of blonanserin vs. haloperidol because there were no new RCTs. Our results suggest that the efficacy of blonanserin for schizophrenia is comparable with that of other antipsychotics, and blonanserin seems to be well tolerated.
DOI 10.1055/a-0574-0088
PMID 29514360